Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with chemotherapy with or without tremelimumab versus chemotherapy in first-line advanced urothelial cancer
2024-510976-19-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of durvalumab and tiragolumab in transitional cell carcinoma (TCC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Overall survival. Planned start Nov 2018; status: authorised.
02
Drugs
durvalumabtiragolumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-510976-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510976-19-00.